NCT00000641 - A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

December 31, 1994

Conditions

Mycobacterium Avium-intracellulare InfectionHIV Infections

Interventions

DRUG

Ciprofloxacin hydrochloride

DRUG

Ethambutol hydrochloride

DRUG

Amikacin sulfate

DRUG

Azithromycin

DRUG

Rifampin

DRUG

Clofazimine

Trial Locations (16)

10016

NY Univ. HIV/AIDS CRS, New York

14642

Univ. of Rochester ACTG CRS, Rochester

15213

Pitt CRS, Pittsburgh

27599

Unc Aids Crs, Chapel Hill

27710

Duke Univ. Med. Ctr. Adult CRS, Durham

44106

Case CRS, Cleveland

45267

Univ. of Cincinnati CRS, Cincinnati

46202

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

90502

Harbor-UCLA Med. Ctr. CRS, Torrance

98122

University of Washington AIDS CRS, Seattle

Unknown

St. Louis ConnectCare, Infectious Diseases Clinic, St Louis

Washington U CRS, St Louis

Beth Israel Med. Ctr. (Mt. Sinai), New York

NYU Med. Ctr., Dept. of Medicine, New York

Regional Center for Infectious Disease, Wendover Medical Center CRS, Greensboro

07103

NJ Med. School CRS, Newark

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH